All Updates

All Updates

icon
Filter
M&A
Eli Lilly acquires Morphic Holding for USD 3.2 billion to expand immunology pipeline
Precision Medicine
Jul 8, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Precision Medicine

Precision Medicine

Jul 8, 2024

Eli Lilly acquires Morphic Holding for USD 3.2 billion to expand immunology pipeline

M&A

  • Eli Lilly has announced the acquisition of Morphic Holding, a biopharmaceutical company specializing in oral integrin therapies for chronic diseases. As per the definitive agreement, Lilly will acquire all outstanding shares of Morphic for USD 57 per share. The transaction is valued at ~USD 3.2 billion and is expected to close in Q3 2024.

  • Post-acquisition, Lilly plans to expand its immunology portfolio and develop new therapies in gastroenterology. Morphic's main product is an oral molecule known as "MORF-057," which inhibits α4β7 integrin, a protein implicated in inflammatory bowel disease. It is being tested in two Phase II trials for ulcerative colitis and Phase I trials for Crohn's disease. 

  • Eli Lilly and Company is a global pharmaceutical company committed to creating high-quality medicines that address unmet medical needs. The company is focused on neuroscience, cardiometabolic, cancer, and immunology disease areas. Key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, Humulin for diabetes, and Taltz and Olumiant for immunology.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.